Investors sold shares of Johnson & Johnson (NYSE:JNJ) on strength during trading hours on Monday. $88.73 million flowed into the stock on the tick-up and $138.30 million flowed out of the stock on the tick-down, for a money net flow of $49.57 million out of the stock. Of all stocks tracked, Johnson & Johnson had the 0th highest net out-flow for the day. Johnson & Johnson traded up $0.88 for the day and closed at $119.92

Several equities research analysts have commented on JNJ shares. BTIG Research cut shares of Johnson & Johnson from a “buy” rating to a “neutral” rating in a research report on Thursday, May 12th. Morgan Stanley reiterated a “hold” rating on shares of Johnson & Johnson in a research report on Thursday, May 19th. Wells Fargo & Co. reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Monday, July 11th. BMO Capital Markets reiterated an “outperform” rating and issued a $132.00 price target on shares of Johnson & Johnson in a research report on Wednesday, July 20th. Finally, Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 price target on the stock in a research report on Friday, August 5th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $119.53.

The firm has a 50 day moving average of $122.84 and a 200-day moving average of $114.62. The company has a market capitalization of $328.09 billion and a PE ratio of 22.35.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.68 by $0.06. The firm had revenue of $18.50 billion for the quarter, compared to analyst estimates of $17.98 billion. Equities research analysts predict that Johnson & Johnson will post $6.69 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 19th. Shareholders of record on Friday, August 5th were issued a $0.29 dividend. This represents a $1.16 annualized dividend and a yield of 0.97%.

In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 2,935 shares of Johnson & Johnson stock in a transaction on Friday, July 22nd. The stock was sold at an average price of $125.01, for a total value of $366,904.35. Following the completion of the transaction, the chief accounting officer now directly owns 28,660 shares of the company’s stock, valued at approximately $3,582,786.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Ronald A. Kapusta sold 3,000 shares of Johnson & Johnson stock in a transaction on Tuesday, June 7th. The shares were sold at an average price of $115.79, for a total value of $347,370.00. Following the completion of the transaction, the chief accounting officer now directly owns 28,725 shares of the company’s stock, valued at $3,326,067.75. The disclosure for this sale can be found here.

A number of institutional investors recently made changes to their positions in JNJ. CG Asset Management LLC boosted its position in shares of Johnson & Johnson by 0.3% in the fourth quarter. CG Asset Management LLC now owns 55,737 shares of the company’s stock valued at $5,725,000 after buying an additional 181 shares in the last quarter. Spectrum Advisory Services Inc. boosted its position in shares of Johnson & Johnson by 0.7% in the fourth quarter. Spectrum Advisory Services Inc. now owns 32,603 shares of the company’s stock valued at $3,349,000 after buying an additional 234 shares in the last quarter. Holderness Investments Co. boosted its position in shares of Johnson & Johnson by 2.1% in the fourth quarter. Holderness Investments Co. now owns 14,942 shares of the company’s stock valued at $1,535,000 after buying an additional 302 shares in the last quarter. Bruni J V & Co. Co. boosted its position in shares of Johnson & Johnson by 0.9% in the fourth quarter. Bruni J V & Co. Co. now owns 39,669 shares of the company’s stock valued at $4,075,000 after buying an additional 344 shares in the last quarter. Finally, Marco Investment Management LLC boosted its position in shares of Johnson & Johnson by 2.3% in the fourth quarter. Marco Investment Management LLC now owns 48,052 shares of the company’s stock valued at $4,936,000 after buying an additional 1,100 shares in the last quarter.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.